Studentized permutation method for comparing two restricted mean survival times with small sample from randomized trials
- PMID: 37070141
- PMCID: PMC11620287
- DOI: 10.1002/sim.9720
Studentized permutation method for comparing two restricted mean survival times with small sample from randomized trials
Abstract
Recent observations, especially in cancer immunotherapy clinical trials with time-to-event outcomes, show that the commonly used proportional hazard assumption is often not justifiable, hampering an appropriate analysis of the data by hazard ratios. An attractive alternative advocated is given by the restricted mean survival time (RMST), which does not rely on any model assumption and can always be interpreted intuitively. Since methods for the RMST based on asymptotic theory suffer from inflated type-I error under small sample sizes, a permutation test was proposed recently leading to more convincing results in simulations. However, classical permutation strategies require an exchangeable data setup between comparison groups which may be limiting in practice. Besides, it is not possible to invert related testing procedures to obtain valid confidence intervals, which can provide more in-depth information. In this paper, we address these limitations by proposing a studentized permutation test as well as respective permutation-based confidence intervals. In an extensive simulation study, we demonstrate the advantage of our new method, especially in situations with relatively small sample sizes and unbalanced groups. Finally, we illustrate the application of the proposed method by re-analyzing data from a recent lung cancer clinical trial.
Keywords: hazard ratio; permutation methods; restricted mean survival time; survival analysis; time-to-event outcomes.
© 2023 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
Conflict of interest
The authors declare no potential conflict of interests.
Figures



Similar articles
-
On permutation tests for comparing restricted mean survival time with small sample from randomized trials.Stat Med. 2020 Sep 10;39(20):2655-2670. doi: 10.1002/sim.8565. Epub 2020 May 20. Stat Med. 2020. PMID: 32432805
-
Design of non-inferiority randomized trials using the difference in restricted mean survival times.Clin Trials. 2018 Oct;15(5):499-508. doi: 10.1177/1740774518792259. Epub 2018 Aug 3. Clin Trials. 2018. PMID: 30074407 Free PMC article.
-
Restricted mean survival time to estimate an intervention effect in a cluster randomized trial.Stat Methods Med Res. 2023 Oct;32(10):2016-2032. doi: 10.1177/09622802231192960. Epub 2023 Aug 9. Stat Methods Med Res. 2023. PMID: 37559486 Clinical Trial.
-
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.J Clin Oncol. 2016 May 20;34(15):1813-9. doi: 10.1200/JCO.2015.64.2488. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884584 Review.
-
Quantifying treatment differences in confirmatory trials under non-proportional hazards.J Appl Stat. 2020 Sep 3;49(2):466-484. doi: 10.1080/02664763.2020.1815673. eCollection 2022. J Appl Stat. 2020. PMID: 35707213 Free PMC article. Review.
Cited by
-
Early and Late Buzzards: Comparing Different Approaches for Quantile-Based Multiple Testing in Heavy-Tailed Wildlife Research Data.Biom J. 2025 Aug;67(4):e70065. doi: 10.1002/bimj.70065. Biom J. 2025. PMID: 40614164 Free PMC article.
-
Multi-group global tests for restricted mean survival time and restricted mean time lost: a variable transformation approach.BMC Med Res Methodol. 2025 May 3;25(1):123. doi: 10.1186/s12874-025-02563-9. BMC Med Res Methodol. 2025. PMID: 40319248 Free PMC article.
References
-
- Trinquart L, Jacot J, Conner S, Porcher R. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. Journal of Clinical Oncology 2016; 34(15): 1813–1819. - PubMed
-
- Mick T, Chen TT. Statistical challenges in the design of late-stage cancer immunotherapy studies. Cancer Immunology Research 2015; 3(12): 1292–1298. - PubMed
-
- Alexander B, Schoenfeld J, Trippa L. Hazards of hazard ratios-deviations from model assumptions in immunotherapy. The New England Journal of Medicine 2018; 378(12): 1158–1159. - PubMed
-
- Zittoun R, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine 1995; 332(4): 217–223. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources